Table 2.
Variable | PD Executive (n=25) | PD Memory (n=35) | PD Cognitively Well (n=56) | Non-PD (n=62) | p-value |
---|---|---|---|---|---|
Brain Volumes (cm3) | |||||
Total Intracranial | 1699 ± 161 1395/2047 | 1711 ± 140 1435/2112 | 1650 ± 147 1263/1928 | 1623 ± 131 1343/1887 | .02* |
Ventricle Volume | 54.45 ± 33.22 7.93/147.01 | 34.08 ± 18.08, 11.31/87.49 | 34.54 ± 16.14, 9.35/78.39 | 29.78 ± 14.12, 6.74/65.52 | <.01* |
Brain Volume | 1101 ± 83.0 973/1283 | 1150±113.3 946/1526 | 1106 ± 99.87 805/1307; 1145 | 1091 ± 96.65 906/1306 | <.01* |
Total Gray Matter Volume | 620.08 ± 50.76 514.26/745.92 | 635.48 ± 57.82 522.22/826.68 | 619.62 ± 50.25 459.54/714.02 | 619.06 ± 48.24 523.85/734.14 | <.01 |
Cortex Volume | 458.29 ± 40.87 373.42/555.65 | 473.90 ± 46.22 387.58/627.46 | 458.73 ± 39.87 343.91/551.97 | 459.48 ± 38.89 388.29/558.97 | <.01 |
Subcortical Grey Volume | 53.96 ± 3.88 47.83/61.31 | 56.85 ± 5.69 45.90/71.68 | 54.81 ± 5.26 41.18/64.54 | 54.40 ± 4.80 46.03/66.11 | .02* |
White Matter Volume | 454.83±37.51 375.51/534.85 | 484.07±59.45 401.51/667.24 | 460.09±53.91 329.04/612.48 | 446.70±53.02 340.65/581.36 | <.01* |
Hippocampus Volume | 3.68±0.33 3.17/4.31 | 3.93±0.44 2.97/5.07 | 3.86±0.38 3.12/4.86 | 3.87±0.43 2.87/4.94 | <.01* |
Caudate Volume | 3.55±0.64 2.61/5.60 | 3.54±0.64, 2.41/6.03 | 3.43±0.52 2.39/4.64 | 3.44±0.53 2.43/5.41 | .67 |
Putamen Volume | 4.42±0.35 3.76/5.10 | 4.66±0.73 3.58/7.28 | 4.43±0.67 2.70/5.84 | 4.64±0.53 3.50/5.94 | .02 |
Thalamus Volume | 6.75±0.64 5.51/8.05 | 7.07±0.76 5.38/8.79 | 6.91±0.79 4.73/9.59 | 6.61±0.67 5.21/8.32 | .04 |
Cortical Thickness (mm) | |||||
ERC Thickness | 3.30±0.27 2.53/3.75 | 3.32±0.24 2.86/3.74 | 3.32±0.23 2.77/3.86 | 3.36±0.4 2.80/3.84 | .64 |
DLPFC Thickness | 2.34±0.10 2.11/2.47 | 2.36±0.09 2.16/2.54 | 2.35±0.09 2.17/2.56 | 2.36±0.09 2.11/2.5 | .83 |
All values reported as Mean±SD, Min/Max. All volumes reported in cm3; thickness is presented in mm. ERC=Entorhinal Cortex. DLPFC=Dorsolateral Prefrontal Cortex.
indicates significant difference between PD phenotypes after controlling for disease duration.